<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04911842</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN 21-001</org_study_id>
    <nct_id>NCT04911842</nct_id>
  </id_info>
  <brief_title>Midline Failures: A Comparison Between a Hydrophilic Biomaterial and Thermoplastic Polyurethane</brief_title>
  <official_title>Midline Failures: A Comparative, Retrospective Chart Review</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Access Vascular Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Access Vascular Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective chart review to evaluate and compare the rate of failures between midlines made&#xD;
      from different materials&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this chart review is to evaluate the rates of failure of midlines made from different materials.</measure>
    <time_frame>retrospective review- March 2021 through May 2021</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the proportion of times the midline was used to successfully complete prescribed length.</measure>
    <time_frame>retrospective review- March 2021 through May 2021</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Midline Catheter</condition>
  <arm_group>
    <arm_group_label>TPU</arm_group_label>
    <description>Thermoplastic polyurethane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBM</arm_group_label>
    <description>Hydrophilic BioMaterial</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HydroMID</intervention_name>
    <description>Hydrophilic biomaterial</description>
    <arm_group_label>HBM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TPU</intervention_name>
    <description>Thermoplastic polyurethane</description>
    <arm_group_label>TPU</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who needed a 4 Fr single lumen midline&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who have been inserted with the HydroMID by the vascular access group&#xD;
&#xD;
          -  Subjects who have been inserted with a competitor 4 Fr single lumen by the vascular&#xD;
             access team&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any off-label use (PICC lines cut to be midlines for any manufacturer)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Joseph Bunch</name>
      <address>
        <city>Romeoville</city>
        <state>Illinois</state>
        <zip>60446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

